Adipocyte-secreted factors increase osteoblast proliferation and the OPG/RANKL ratio to influence osteoclast formation

Molecular and Cellular Endocrinology

Volumn 349, Issue 2, 2012, Pages 180-188

  Kühn, Markus C ^a   Willenberg, Holger S ^a   Schott, Matthias ^a   Papewalis, Claudia ^a   Stumpf, Ulla ^a   Flohé, Sascha ^a   Scherbaum, Werner A ^a   Schinner, Sven ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Aadipocytes; BFGF; Obesity; OPG RANKL ratio; Osteoblasts; Osteoporosis

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RESISTIN; FGFR1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL GENE; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR DYNAMICS; NONHUMAN; OSTEOBLAST; OSTEOCLAST DIFFERENTIATION FACTOR GENE; OSTEOCLASTOGENESIS; OSTEOPROTEGERIN GENE; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION; WNT SIGNALING PATHWAY; ADIPOCYTE; ANIMAL; BONE DEVELOPMENT; CELL CULTURE; CULTURE MEDIUM; CYTOLOGY; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; METABOLISM; MOUSE; OSTEOCLAST; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SECRETION;

ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA, MESSENGER;

EID: 84862604082     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.10.018     Document Type: Article

References (56)

1. Agas D., Marchetti L., Menghi G., Materazzi S., Materazzi G., Capacchietti M., Hurley M.M., Sabbieti M.G. Anti-apoptotic Bcl-2 enhancing requires FGF-2/FGF receptor 1 binding in mouse osteoblasts. J. Cell Physiol. 2008, 214:145-152.
2. Alliston T., Derynck R. Medicine: interfering with bone remodelling. Nature 2002, 416:686-687.
3. Baksh D., Boland G.M., Tuan R.S. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J. Cell Biochem. 2007, 101:1109-1124.
4. Beck T.J., Petit M.A., Wu G., LeBoff M.S., Cauley J.A., Chen Z. Does obesity really make the femur stronger? BMD, geometry, and fracture incidence in the women's health initiative-observational study. J. Bone Miner. Res. 2009, 24:1369-1379.
5. Bellido T., Borba V.Z., Roberson P., Manolagas S.C. Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 1997, 138:3666-3676.
6. Benayahu D., Zipori D., Wientroub S. Marrow adipocytes regulate growth and differentiation of osteoblasts. Biochem. Biophys. Res. Commun. 1993, 197:1245-1252.
7. Boland G.M., Perkins G., Hall D.J., Tuan R.S. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J. Cell Biochem. 2004, 93:1210-1230.
8. Borgstrom F., Sobocki P., Strom O., Jonsson B. The societal burden of osteoporosis in Sweden. Bone 2007, 40:1602-1609.
9. Borgstrom F., Zethraeus N., Johnell O., Lidgren L., Ponzer S., Svensson O., Abdon P., Ornstein E., Lunsjo K., Thorngren K.G., Sernbo I., Rehnberg C., Jonsson B. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos. Int. 2006, 17:637-650.
10. Bovolenta P., Esteve P., Ruiz J.M., Cisneros E., Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J. Cell Sci. 2008, 121:737-746.
11. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J. Bone Miner. Res. 2007, 22:465-475.
12. Clark P., Carlos F., Barrera C., Guzman J., Maetzel A., Lavielle P., Ramirez E., Robinson V., Rodriguez-Cabrera R., Tamayo J., Tugwell P. Direct costs of osteoporosis and hip fracture: an analysis for the Mexican healthcare system. Osteoporos. Int. 2008, 19:269-276.
13. Colnot C. Cellular and molecular interactions regulating skeletogenesis. J. Cell Biochem. 2005, 95:688-697.
14. Debiais F., Lefevre G., Lemonnier J., Le M.S., Lasmoles F., Mascarelli F., Marie P.J. Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent, -beta-catenin-independent signaling pathway. Exp. Cell Res. 2004, 297:235-246.
15. Dupree M.A., Pollack S.R., Levine E.M., Laurencin C.T. Fibroblast growth factor 2 induced proliferation in osteoblasts and bone marrow stromal cells: a whole cell model. Biophys. J. 2006, 91:3097-3112.
16. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., Langenbach J., Willenberg H.S., Barthel A., Hauner H., McCann S.M., Scherbaum W.A., Bornstein S.R. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl. Acad. Sci. USA 2003, 100:14211-14216.
17. Elbaz A., Wu X., Rivas D., Gimble J.M., Duque G. Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J. Cell Mol. Med. 2010, 14:982-991.
18. Fischer-Posovszky P., Wabitsch M., Hochberg Z. Endocrinology of adipose tissue - an update. Horm. Metab. Res. 2007, 39:314-321.
19. Gabrielsson B.G., Johansson J.M., Jennische E., Jernas M., Itoh Y., Peltonen M., Olbers T., Lonn L., Lonroth H., Sjostrom L., Carlsson B., Carlsson L.M., Lonn M. Depot-specific expression of fibroblast growth factors in human adipose tissue. Obes. Res. 2002, 10:608-616.
20. Gnudi S., Sitta E., Fiumi N. Relationship between body composition and bone mineral density in women with and without osteoporosis: relative contribution of lean and fat mass. J. Bone Miner. Metab. 2007, 25:326-332.
21. Gnudi S., Sitta E., Lisi L. Relationship of body mass index with main limb fragility fractures in postmenopausal women. J. Bone Miner. Metab. 2009, 27:479-484.
22. Gomez-Ambrosi J., Rodriguez A., Catalan V., Fruhbeck G. The bone-adipose axis in obesity and weight loss. Obes. Surg. 2008, 18:1134-1143.
23. Haase M., Schott M., Bornstein S.R., Malendowicz L.K., Scherbaum W.A., Willenberg H.S. CITED2 is expressed in human adrenocortical cells and regulated by basic fibroblast growth factor. J. Endocrinol. 2007, 192:459-465.
24. Haussler B., Gothe H., Gol D., Glaeske G., Pientka L., Felsenberg D. Epidemiology, treatment and costs of osteoporosis in Germany-the BoneEVA Study. Osteoporos. Int. 2007, 18:77-84.
25. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
26. Hoemann C.D., El-Gabalawy H., McKee M.D. In vitro osteogenesis assays: influence of the primary cell source on alkaline phosphatase activity and mineralization. Pathol. Biol. (Paris) 2009, 57:318-323.
27. Johnell O., Kanis J. Epidemiology of osteoporotic fractures. Osteoporos.Int. 2005, 16(Suppl. 2):S3-S7.
28. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 2006, 17:1726-1733.
29. Kinjo M., Setoguchi S., Solomon D.H. Bone mineral density in adults with the metabolic syndrome: analysis in a population-based US Sample. J. Clin. Endocrinol. Metab. 2007, 92:4161-4164.
30. Konnopka A., Jerusel N., Konig H.H. The health and economic consequences of osteopenia- and osteoporosis-attributable hip fractures in Germany: estimation for 2002 and projection until 2050. Osteoporos. Int. 2009, 20:1117-1129.
31. Kuznetsov S., Gehron R.P. Species differences in growth requirements for bone marrow stromal fibroblast colony formation In vitro. Calcif. Tissue Int. 1996, 59:265-270.
32. Li Y., Backesjo C.M., Haldosen L.A., Lindgren U. IL-6 receptor expression and IL-6 effects change during osteoblast differentiation. Cytokine 2008, 43:165-173.
33. Marinou K., Tousoulis D., Antonopoulos A.S., Stefanadi E., Stefanadis C. Obesity and cardiovascular disease: from pathophysiology to risk stratification. Int. J. Cardiol. 2010, 138:3-8.
34. Maurin A.C., Chavassieux P.M., Frappart L., Delmas P.D., Serre C.M., Meunier P.J. Influence of mature adipocytes on osteoblast proliferation in human primary cocultures. Bone 2000, 26:485-489.
35. Maurin A.C., Chavassieux P.M., Vericel E., Meunier P.J. Role of polyunsaturated fatty acids in the inhibitory effect of human adipocytes on osteoblastic proliferation. Bone 2002, 31:260-266.
36. Moursi A.M., Winnard P.L., Winnard A.V., Rubenstrunk J.M., Mooney M.P. Fibroblast growth factor 2 induces increased calvarial osteoblast proliferation and cranial suture fusion. Cleft Palate Craniofac. J. 2002, 39:487-496.
37. Nauman E.A., Sakata T., Keaveny T.M., Halloran B.P., Bikle D.D. BFGF administration lowers the phosphate threshold for mineralization in bone marrow stromal cells. Calcif. Tissue Int. 2003, 73:147-152.
38. Nguyen N.D., Pongchaiyakul C., Center J.R., Eisman J.A., Nguyen T.V. Abdominal fat and hip fracture risk in the elderly: the Dubbo Osteoporosis Epidemiology Study. BMC. Musculoskelet. Disord. 2005, 6:11.
39. Consensus NIH Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South Med J 2001, 94.
40. Park S.J., Kim S.J., Rhee Y., Byun J.H., Kim S.H., Kim M.H., Lee E.J., Lim S.K. Fidgetin-like 1 gene inhibited by basic fibroblast growth factor regulates the proliferation and differentiation of osteoblasts. J. Bone Miner. Res. 2007, 22:889-896.
41. Patel N.G., Kumar S., Eggo M.C. Essential role of fibroblast growth factor signaling in preadipoctye differentiation. J. Clin. Endocrinol. Metab 2005, 90:1226-1232.
42. Rasouli N., Kern P.A. Adipocytokines and the metabolic complications of obesity. J. Clin. Endocrinol. Metab. 2008, 93:S64-S73.
43. Reid I.R. Relationships between fat and bone. Osteoporos. Int. 2008, 19:595-606.
44. Sakaguchi Y., Sekiya I., Yagishita K., Ichinose S., Shinomiya K., Muneta T. Suspended cells from trabecular bone by collagenase digestion become virtually identical to mesenchymal stem cells obtained from marrow aspirates. Blood 2004, 104:2728-2735.
45. Schinner S., Scherbaum W.A., Bornstein S.R., Barthel A. Molecular mechanisms of insulin resistance. Diabet. Med. 2005, 22:674-682.
46. Schinner S., Ulgen F., Papewalis C., Schott M., Woelk A., Vidal-Puig A., Scherbaum W.A. Regulation of insulin secretion, glucokinase gene transcription and beta cell proliferation by adipocyte-derived Wnt signalling molecules. Diabetologia 2008, 51:147-154.
47. Schinner S., Willenberg H.S., Krause D., Schott M., Lamounier-Zepter V., Krug A.W., Ehrhart-Bornstein M., Bornstein S.R., Scherbaum W.A. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int. J. Obes. (Lond) 2007, 31:864-870.
48. Shimoaka T., Ogasawara T., Yonamine A., Chikazu D., Kawano H., Nakamura K., Itoh N., Kawaguchi H. Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10. J. Biol. Chem. 2002, 277:7493-7500.
49. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
50. Stanford C.M., Jacobson P.A., Eanes E.D., Lembke L.A., Midura R.J. Rapidly forming apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP). J. Biol. Chem. 1995, 270:9420-9428.
51. Teplyuk N.M., Haupt L.M., Ling L., Dombrowski C., Mun F.K., Nathan S.S., Lian J.B., Stein J.L., Stein G.S., Cool S.M., van Wijnen A.J. The osteogenic transcription factor Runx2 regulates components of the fibroblast growth factor/proteoglycan signaling axis in osteoblasts. J. Cell Biochem. 2009, 107:144-154.
52. Travison T.G., Araujo A.B., Esche G.R., Beck T.J., McKinlay J.B. Lean mass and not fat mass is associated with male proximal femur strength. J. Bone Miner. Res. 2008, 23:189-198.
53. Uren A., Reichsman F., Anest V., Taylor W.G., Muraiso K., Bottaro D.P., Cumberledge S., Rubin J.S. Secreted frizzled-related protein-1 binds directly to Wingless and is a biphasic modulator of Wnt signaling. J. Biol. Chem. 2000, 275:4374-4382.
54. von, M.D., Safii, S., Jassal, S.K., Svartberg, J., and Barrett-Connor, E., 2007. Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos.Int. 18, 1337-1344.
55. WHO Press Release, 1999. Osteoporosis: Both health organizations and individuals must act now to avoid an impending epidemic. http://www.who.int/inf-pr-1999/en/pr99-58.html.
56. Zhao L.J., Liu Y.J., Liu P.Y., Hamilton J., Recker R.R., Deng H.W. Relationship of obesity with osteoporosis. J. Clin. Endocrinol. Metab. 2007, 92:1640-1646.